The Reply - 23/01/14
Doi : 10.1016/j.amjmed.2013.09.029
Mark S. Klempner, MD a, Phillip J. Baker, PhD b, Eugene D. Shapiro, MD c, Adriana Marques, MD d, Raymond J. Dattwyler, MD e, John J. Halperin, MD f, Gary P. Wormser, MD g
a University of Massachusetts Medical School, Boston, Mass
b American Lyme Disease Foundation, Lyme, Conn
c Departments of Pediatrics, Epidemiology, and Public Health, and Investigative Medicine, Yale University, New Haven, Conn
d National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
e Division of Allergy, Immunology and Rheumatology, Department of Medicine, New York Medical College, Valhalla, NY
f Department of Neurosciences, Overlook Medical Center and Atlantic Neuroscience Institute, Summit, NJ
g Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, NY
Le texte complet de cet article est disponible en PDF.
| Funding: None. |
|
| Conflict of Interest: MSK has received research grants from the Centers for Disease Control and Prevention and National Institutes of Health. PJB has no conflicts of interest associated with the work presented in this manuscript. EDS is a board member of the American Lyme Disease Foundation, for which no compensation is received, and has received compensation from UpToDate for reviewing medical records for the Metropolitan Life Insurance Company and providing medicolegal testimony. AM is co-inventor on a patent application for a test for the detection of anti-Borrelia burgdorferi antibodies in which one of the antigens is based on the IR6 peptide (no money has been paid to her or to her institution): VOVO LIPS test for Lyme disease, US Provisional Application No. 61/312,520 filed March 10, 2010 (HHS Reference No. E-036- 2010/0-US-01). RJD has received research grants from the National Institutes of Health; is part owner of and has stock in Biopeptides Corp, no product of which is referred to in this article; has received payment for providing expert testimony in malpractice cases; and holds patents on vaccine and diagnostic technology with SUNY at Stony Brook and Biopeptides. JJH has served as an expert witness in several medicolegal cases concerning Lyme disease and has equity in Abbott, Bristol-Myers Squibb, Johnson & Johnson, and Merck; no products from these companies are referred to in this article. GPW has received research grants from the Centers for Disease Control and Prevention, National Institutes of Health, Immunetics, Inc, BioRad, DiaSorin, Inc, and BioMerieux; has equity in Abbott; has been an expert witness in malpractice cases involving Lyme disease; is an unpaid board member of the American Lyme Disease Foundation; and been an expert witness regarding Lyme disease in a disciplinary action for the Missouri Board of Registration for the Healing Arts; and is a consultant to Baxter for Lyme vaccine development. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
© 2014
Elsevier Inc. Tous droits réservés.
Vol 127 - N° 2
P. e11-e12 - février 2014 Retour au numéro
Article précédent
- Potential Benefits of Retreatment Highlight the Need for Additional Lyme Disease Research
- Allison K. DeLong, Barbara Blossom, Elizabeth Maloney, Steven E. Phillips
- Does Hypomagnesemia Predict Faster Progression of Nondiabetic Chronic Kidney Disease?
- Yusuke Sakaguchi, Yoshiharu Tsubakihara, Hiromi Rakugi, Yoshitaka Isaka
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?